Monitoring after childhood cancer: An update for GPs

Australian Family Physician

Volumn 34, Issue 9, 2005, Pages 761-767

  Heath, John A ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; CHILD; COGNITIVE DEFECT; ENDOCRINE DISEASE; FEMALE; FERTILITY; GENERAL PRACTICE; GROWTH DISORDER; HEALTH PROMOTION; HUMAN; MALE; METHODOLOGY; NEOPLASM; PSYCHOLOGICAL ASPECT; RADIOTHERAPY; REVIEW; RISK FACTOR; SECOND CANCER; SURVIVOR; TUMOR RECURRENCE;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; COGNITION DISORDERS; ENDOCRINE SYSTEM DISEASES; FAMILY PRACTICE; FEMALE; FERTILITY; GROWTH DISORDERS; HEALTH PROMOTION; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY; RISK FACTORS; SURVIVORS;

EID: 27744595116     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Brenner H. Up-to-date survival curves of children with cancer by period analysis. Br J Cancer 2003;88:1693-7.
2. Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA 2003;290:1583-92.
3. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience
4. Haase GM, Mauer AM, Reaman GH. Survivorship in childhood cancer: a case statement for enhancement of the role of the American Cancer Society. Task Force on Children and Cancer of the American Cancer Society. Cancer 1998;83:821-3.
5. Arceci RJ, Reaman GH, Cohen AR, et al. Position statement for the need to define pediatric hematology/oncology programs: a model of subspecialty care for chronic childhood diseases. Health Care Policy and Public Issues Committee of the American Society of Pediatric Hematology/Oncology. J Pediatr Hematol Oncol 1998;20:98-103.
6. Masera G, Chesler M, Jankovic M, et al. SIOP Working Committee on Psychosocial issues in pediatric oncology: guidelines for care of long term survivors. Med Pediatr Oncol 1996;27:1-2.
7. Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Ped Oncol 2002;38:229-39.
8. Landier W, Bhatia S, Eshelman DA, et al. Development of risk based guidelines for pediatric cancer survivors: the Children's Oncology Group. Long term follow up guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004;22:4979-90.
9. Robertson CM, Hawkins MM, Kingston JE. Late deaths and survival after childhood cancer: implications for cure. BMJ 1994;309:162-6.
10. Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumours among childhood cancer survivors.
11. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukaemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999;17:569-77.
12. Broniscer A, Ke W, Fuller CE, et al. Second neoplasms in pediatric patients with primary central nervous system tumours: the St. Jude Children's Research Hospital experience.
13. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood
14. Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of partners of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2003;21:716-21.
15. Byrne J, Fears TR, Gail MH, et al. Early menopause in long term survivors of cancer during adolescence. Am J Obstet Gynecol 1992;166:788-93.
16. Pereyra-Pacheco B, Mendez-Ribaz JM, Milone G, et al. Use of GnRH analogues for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001;81:391-7.
17. Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am J Obstetrics Gynecol 2002;187:1070-80.
18. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43.
19. Boucek RJ Jr, Steele A, Miracle A, et al. Effects of angiotensin- converting enzyme inhibitor on delayed onset doxorubicin induced cardiotoxicity. Cardiovasc Toxicol 2003;3:319-29.
20. Hollen PJ, Hobbie WL. Decision making and risk behaviours of cancer surviving adolescents and their peers. J Pediatr Oncol Nurs 1996;13:121-33.